Rafferty Asset Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Rafferty Asset Management's NKTR Position: Q3 2026 in Review
Rafferty Asset Management increased its Nektar Therapeutics (NKTR) stake by 1,110% in Q3 2026, buying an estimated $2.73M and bringing the position to 42,332 shares worth $2.56M. The position accounts for 0.01% of the portfolio, ranked #535.
Rafferty Asset Management first reported a position in NKTR in Q3 2019 and has held it in 13 quarters since. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- Rafferty Asset Management held 42,332 shares of Nektar Therapeutics worth $2.56M as of Q3 2026.
- Rafferty Asset Management bought 38,833 Nektar Therapeutics shares in Q3 2026, an estimated $2.73M.
- Nektar Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #535 holding.
- Rafferty Asset Management first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 13 quarters since.
- 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.